Page last updated: 2024-12-08
epsilon n-dimethyllysine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N(6),N(6)-dimethyl-L-lysine : An L-lysine derivative comprising L-lysine having two methyl substituents attached to the side-chain amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 193344 |
CHEBI ID | 43997 |
SCHEMBL ID | 358975 |
MeSH ID | M0070947 |
Synonyms (29)
Synonym |
---|
epsilon n-dimethyllysine |
DB03362 |
n-dimethyl-lysine |
MLY , |
nepsilon-dimethyl-l-lysine hydrochloride |
n(6),n(6)-dimethyl-l-lysine |
n6,n6-dimethyl-l-lysine |
2259-86-1 |
(2s)-2-amino-6-(dimethylamino)hexanoic acid |
n(epsilon),n(epsilon)-dimethyllysine |
CHEBI:43997 |
n(epsilon),n(epsilon)-dimethyl-l-lysine |
n(epsilon)-dimethyllysine |
n(6),n(6)-dimethyllysine |
(s)-2-amino-6-dimethylaminohexanoic acid |
lys(me2) |
n(epsilon)-dimethyl-l-lysine |
n,n-dimethyl lysine |
lys(me)2 |
XXEWFEBMSGLYBY-ZETCQYMHSA-N |
l-lysine, n6,n6-dimethyl- |
SCHEMBL358975 |
n6,n6-dimethyllysine |
n'-dimethyl-l-lysine |
n~6~,n~6~-dimethyl-l-lysine |
n~6~,n~6~-dimethyllysine |
DTXSID60945241 |
Q27104521 |
EN300-1300752 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
L-lysine derivative | A proteinogenic amino acid derivative resulting from reaction of L-lysine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-lysine by a heteroatom. |
non-proteinogenic L-alpha-amino acid | Any L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (57.14) | 18.7374 |
1990's | 2 (14.29) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 1 (7.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.70) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |